Premium
Cyclic αvβ6‐targeting peptide selected from biopanning with clinical potential for head and neck squamous cell carcinoma
Author(s) -
Hsiao JennRen,
Chang Yao,
Chen YuhLing,
Hsieh SuHuei,
Hsu KengFu,
Wang ChunFu,
Tsai SenTien,
Jin YingTai
Publication year - 2010
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.21166
Subject(s) - biopanning , peptide , phage display , head and neck squamous cell carcinoma , peptide library , cancer research , biology , cell , microbiology and biotechnology , integrin , cancer , peptide sequence , head and neck cancer , biochemistry , genetics , gene
Background. A cyclic peptide‐displaying phage library was used for biopanning on oral squamous cell carcinoma (OSCC) cells to identify cancer‐targeting peptides. This study was designed to characterize the receptor specificity of a candidate phage clone/peptide (phage/peptide‐29) and to explore the clinical potential of this peptide.Methods. Immunofluorescent confocal microscopy, phage binding assay, and immunohistochemical studies were used to demonstrate the receptor specificity of phage/peptide‐29. The effect of peptide‐29 on the proliferation of OSCC cells was studied using 3‐dimensional (3D) cell cultures.Results. Phage/peptide‐29 preferentially binds integrin αvβ6 rather than other αv‐associated integrins. Peptide‐29 significantly inhibits the proliferation of OSCC cells in 3D cell cultures. On human pathological sections, phage‐29 targets oral cancer cells in a αvβ6‐dependent manner. Besides, we showed that integrin αvβ6 is universally (94.7%, 36/38) expressed in all major kinds of head and neck squamous cell carcinomas (HNSCC).Conclusions. Peptide‐29 selected from biopanning may have clinical potential for HNSCC. © 2009 Wiley Periodicals, Inc. Head Neck, 2010